December saw shares of Rigel Pharmaceuticals (RIGL 2.48%) drop more than 20%. The tumble happened after Rigel's partner AstraZeneca (AZN 0.76%) released phase 2b data concerning their experimental rheumatoid arthritis drug fostamatinib. While the drug outperformed the placebo, it failed to beat AbbVie's (ABBV 1.30%) Humira. (AbbVie, formerly the branded pharmaceutical division of health care powerhouse Abbott Labs (ABT -0.24%), is now listed on the NYSE). In this video, Motley Fool health care analysts Max Macaluso and Brenton Flynn break down this story for investors.
S&P 500
6,000.36
+1.0%
+$61.06
DJI
42,762.87
+1.0%
+$443.13
NASDAQ
19,529.95
+1.2%
+$231.50
Bitcoin
105,845.00
+1.4%
+1,422.01
AAPL
$204.23
+1.8%
+$3.60
AMZN
$213.68
+2.8%
+$5.77
GOOG
$174.93
+3.0%
+$5.12
META
$698.00
+2.0%
+$13.38
MSFT
$470.38
+0.6%
+$2.70
NVDA
$141.76
+1.3%
+$1.77
TSLA
$295.66
+3.8%
+$10.96
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.